J

Johnson & Johnson

Makes prescription drugs and medical devices

IDAR Intern - EASE

Summer 2027Deadline 11/9/26
$23.50 - $52.50/hr
Internship
Bachelor's, Master's, MBA
Spring House, PA, USA+2 moreMore locations: Raritan, NJ, USA | Hopewell Township, NJ, USA
HybridHybrid work; the role-specific description names Raritan, NJ or Spring House, PA; ATS also lists Titusville, NJ.
Data & AnalyticsData Analysis
No H1B Sponsorship

About the job

Requirements
  • Candidates must have completed their undergraduate freshman year at an accredited university.
  • Candidates must be actively enrolled at an accredited university for the duration of the internship while pursuing a Bachelor's, Master's, and/or MBA degree in Data Science, Computer Science, Engineering, health-related disciplines, scientific disciplines, or other related quantitative or technical fields.
  • Candidates must have a cumulative GPA of 3.5 or higher across all college coursework.
  • Candidates must have strong analytical and problem-solving skills.
  • Candidates must be able to understand and learn computer systems concepts, new technologies, and digital tools.
  • Candidates must be able to work effectively independently and within a collaborative, cross-functional environment.
  • Candidates must be permanently authorized to work in the United States and must not require employment visa sponsorship now or in the future.
Responsibilities
  • Support data, analytics, systems, and process-related initiatives within the EASE organization.
  • Apply analytical and problem-solving skills to support clinical trial processes and operational activities.
  • Support the evaluation and application of artificial intelligence-powered tools and frameworks to clinical development use cases.
  • Contribute to initiatives that leverage artificial intelligence to support automation, data analysis, operational efficiency, and decision-making.
  • Support activities focused on improving data quality and generating actionable insights across clinical trial planning and execution.
  • Work with team members to understand business and system needs and contribute to technology-enabled solutions.
  • Learn and adapt to new technologies, systems, analytical approaches, and digital tools.
  • Collaborate with cross-functional partners on assigned projects and initiatives.
  • Document project activities, findings, and recommendations, and communicate results to relevant stakeholders.
  • Provide additional project support as needed.
Desired Qualifications
  • Interest or experience in data analytics, data science, computer systems, or technology-enabled process improvement.
  • Familiarity with artificial intelligence, artificial intelligence-powered tools, or related emerging technologies.
  • Interest in applying artificial intelligence and automation to improve processes, data quality, analysis, and decision-making.
  • Familiarity with data collection, analysis, visualization, or interpretation.
  • Interest in clinical research, clinical trials, pharmaceutical research and development, or drug development.
  • Ability to quickly learn and adapt to new technology platforms, tools, and systems.
  • Strong communication and presentation skills.
  • Strong organizational skills with the ability to manage multiple activities and priorities.
  • Demonstrated initiative, curiosity, adaptability, and collaborative problem-solving skills.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

6 month growth

7%

1 year growth

-1%

2 year growth

-1%
The Irish Times
Oct 28th, 2026
Johnson & Johnson buys Irish stroke care firm in multimillion euro deal

Sale of Neuravi is largest deal for a venture-backed medtech in Europe since 2009

Associated Press
Oct 27th, 2026
Pomerantz investigates Johnson & Johnson after 5.73% share drop on talc charges and MedTech miss

Pomerantz LLP is investigating whether Johnson & Johnson (J&J) and some of its officers or directors engaged in securities fraud or other unlawful business practices. The law firm advises affected investors to contact Danielle Peyton at [email protected]. On October 13, 2026, J&J reported third-quarter GAAP net earnings of $210 million, or $0.09 per share. Multi-billion dollar special charges tied to its talc litigation settlement weighed on the result. Its MedTech segment grew only 2.5% to $8.64 billion, a second straight revenue miss. J&J cited pricing constraints in China and disruption in the Middle East. The stock fell $15.12, or 5.73%, to close at $248.61 that day.

Yahoo Finance
Oct 27th, 2026
J&J sees $34.7M net ETF outflow, extending selling streak to four days

ETFs sold a net $34.7 million of Johnson & Johnson stock on Friday, October 23, extending a four-day run of net selling. SPY led the move, cutting $34.6 million, or 0.44% of its stake. XLV sold $24.6 million and DIA $6.3 million. More funds bought than sold, with 26 ETFs adding shares and 17 cutting them, but their purchases were smaller. Net outflows were $55.2 million on October 22, $54.1 million on October 21, and $19.8 million on October 20. A net inflow of $38.1 million came on October 19. Johnson & Johnson has a market cap of $641.1 billion. It reported $99.35 billion in trailing-12-month revenue, up 7.0% over one year.

Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 23rd, 2026
Smith & Nephew's $22B talks to buy J&J's orthopaedics unit collapse over who would lead

Smith & Nephew's merger talks with Johnson & Johnson (J&J) over its orthopaedics unit collapsed over who would lead the combined company, the Financial Times reported. The sides had reportedly agreed on the main financial terms and the deal structure. J&J wanted Namal Nawana, who runs its orthopaedics unit and formerly led Smith & Nephew, to lead the business. Smith & Nephew wanted current chief executive officer Deepak Nath to stay. Smith & Nephew's offer valued J&J's hip and knee unit at up to $22 billion, almost double its own market value. J&J shareholders would have owned 50.1% of the combined company. J&J is leaning toward spinning off the unit as DePuy Synthes, targeting mid-2027. Reuters reported the unit sought around $20 billion and drew private equity interest. Both companies declined to comment.